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Abstract 
 
Background  
Post-myocardial infarction (MI) ventricular septal defect (VSD) is associated with 
40% - 50% of peri-procedural mortalities; however, it is amenable to catheter-
based therapies. We retrospectively investigated the impact of state-of-the-art 
bridging percutaneous left ventricular mechanical circulatory support (MCS) using 
the TandemHeart® (TH) ventricular assist device (VAD) on a patient with post-MI 
VSD. 
Results 
From July 2008 to March 2014, 23 patients were referred for treatment of post-MI 
VSD. Initially, 18/23 patients required MCS; 12 received an intra-aortic balloon 
pump (IABP), while 6 received initial TH support. Seven of the IABP patients later 
required TH support. Catheter-based device VSD closure was performed in 18 of 
the patients; however, three patients required conversion to conventional open 
cardiac surgical repair via VSD patch closure due to failure of the catheter-based 
approach. Five patients with TH underwent planned open cardiac surgical repair 
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due to an anticipated lack of suitability for catheter-based treatment. Results 
revealed that delayed closure after MI correlated with improved survival. Overall, 
30-day and 6-month survival rates were 83% (19/23) and 70% (16/23), 
respectively.   
Conclusions 
Further, Qp/Qs ratios of <2.4 correlated with successful percutaneous VSD repair, 
and this assessment should be further explored as an assessment to inform 
clinical judgment in patients with post-MI VSD treatment. 
 
Keywords: Ventricular septal defect, mechanical circulatory support, 
percutaneous repair, heart failure 
 
 
 
Introduction 
Mechanical complications of acute myocardial infarction (MI) – ventricular septal 
defect (VSD), mitral regurgitation (MR), and free wall rupture (FWR) carry a grave 
prognosis and contribute to substantial mortality and morbidity despite current 
therapies. However, these complications are historically uncommon, with a 
reported incidence of 1 to 2% in the pre-thrombolytic agent era.1,2 Furthermore, in 
the era of early myocardial reperfusion via percutaneous coronary intervention and 
thrombolytic agents, the incidence of mechanical complications is even lower; the 
incidence of VSD with thrombolysis is as low as 0.2%.3,4 In addition, with the 
advent of reperfusion strategies, the time to ventricular rupture is significantly 
shorter, as documented by the GUSTO1 (Global Utilization of Streptokinase and 
Tissue Plasminogen Activator for Occluded Coronary Arteries/1 Day) and SHOCK 
(Should We Emergently Revascularize Occluded Coronaries for Cardiogenic 
Shock/16 hours) trials.3,5 
While FWR carries the highest mortality, due to its presentation with acute cardiac 
tamponade and obstructive shock, VSD and MR continue to carry high mortalities 
and morbidities as well. Unlike post-MI papillary muscle rupture causing MR, both 
surgical and catheter-based treatment options exist for VSD. Broadly, two types of 
surgical approaches have been used for post-MI VSD. The first approach, 
developed by Daggett and colleagues,6 involves trans-infarct left ventriculotomy, 
infarctectomy, and closure of the VSD, which typically uses a patch prosthesis. 
The second and more recent approach is credited to David and colleagues,7-9 and 
it employs trans-infarct left ventriculotomy with an oversized left-sided patch 
prosthesis sutured to the left-sided septum and anterior left ventricular (LV) walls 
to “exclude” the defect and commit the infarcted septum to the right ventricular 
(RV) side of the patch. 
With respect to surgical treatment, Arnaoutakis and colleagues, in the largest 
study of its kind, reported outcomes of surgical repair of post-MI VSD from the 
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Society of Thoracic Surgeons database.10 In this study, 2,876 patients underwent 
post-MI VSD repair, with a perioperative mortality of 42.9%.10 Patients undergoing 
treatment within 7 days of hospital admission had a 54.1% mortality rate, while the 
minority of patients who underwent delayed treatment had an 18.4% mortality rate. 
While these different survival outcomes may reflect improved hemodynamic and 
clinical conditions of the patients undergoing delayed VSD repair, the magnitude of 
the findings is striking, and suggests that, if feasible, physiological optimization 
both pharmacologically and via mechanical circulatory support (MCS) should be 
undertaken prior to VAD repair. In fact, this was proposed by Dr. T. David in his 
discussion of Arnaoutakis et al.10 Consistent with this hypothesis, we recently 
reported improved outcomes of delayed post-MI VSD surgical repair following a 
period of TandemHeart® (TH, LiveNova, London UK) percutaneous ventricular 
assist device (pVAD) support. Using this approach, we observed a 25% mortality 
rate at six months.11 
The current guidelines recommend emergent surgical repair of the VSD with 
concurrent myocardial revascularization via coronary artery bypass grafting, if 
indicated, irrespective of hemodynamic status.12 However, the high mortality and 
morbidity, as well as an increasing experience with catheter-based device closure 
of congenital VSDs,13,14 have demanded the development of a comprehensive 
reassessment. Our proposed multi-pronged strategy for post-MI VSD management 
is as follows: (1) hemodynamic optimization using pharmacotherapy and MCS in 
the form of either intra-aortic balloon pump (IABP) counterpulsation or when 
needed, TH pVAD support, and (2) delayed catheter-based device and/or open 
cardiac surgical closure. To investigate the effectiveness of this strategy, 
outcomes of patients who underwent this approach of bridging MCS to delayed 
definitive treatment were retrospectively reviewed and analyzed. 
 
Methods 
Between July 2008 and March 2014, 23 patients were referred to our Center in a 
large metropolitan medical center for the management of post-MI VSDs. None of 
the patients had undergone emergent catheter-based or surgical VSD closure. All 
referred patients with post-MI VSDs were included in this study, without exclusion. 
The adequacy of end-organ perfusion and the presence or absence of cardiogenic 
shock was assessed as our Center has previously outlined in the surgical cases 
series by Gregoric et al.11 Pharmacological optimization, comprised of LV afterload 
reduction and inotropic support, was initiated in all 23 patients. Patients who did 
not stabilize and had less severe, low-systemic cardiac output syndrome/shock 
underwent initial percutaneous IABP placement. In contrast, those with severe 
shock either initially or despite IABP support underwent percutaneous trans-atrial 
septal left atrial (LA) and common femoral arterial cannulation for TH pVAD 
support described in Gregoric et al.11 This algorithm is outlined in Figure 1.  
The decision to implement TH versus IAPB was exclusively based on clinical 
judgment. The primary step was to achieve satisfactory cardiovascular status, as 
assessed by systemic arterial blood pressure, Qs, central venous oximetry, and 
clinical and laboratory indices of end-organ perfusion. The decision to wean from 
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Figure 1. Strategy utilized for timing and therapeutic option in the management of 
post-myocardial infarction ventricular septal defects. MI (myocardial infarction); 
VSD (ventricular septal defect); IAPB (intra-aortic balloon pump); TH 
(TandemHeart™); Qp/Qs ( pulmonary/systemic blood flow). 
 
 
 
TH was attempted in the presence of adequate hemodynamics and an improved 
end-organ function at a pVAD flow rate of 2 L/day for two days. While on pVAD, 
the flow rate was adjusted to maintain mixed venous oxygen saturation >70 and 
mean arterial pressure >60 mmHg. 
Qualitative and quantitative assessment of VSD physiology was accomplished 
using echocardiography and diagnostic right-sided cardiac catheterization with 
oximetry. Each of these modalities was used to determine pulmonary and systemic 
blood flow (Qp and Qs, respectively), thereby quantifying intracardiac shunt 
capability in all patients.  
Patients who underwent successful percutaneous closure were implanted with the 
Amplatzer® post-infarction VSD occluder device, the Amplatzer® muscular VSD 
closure device, or the Atrial Septal Occluder (ASO) device (all St. Jude Medical, 
Inc., St. Paul, MN, USA). The implantation strategy included femoral arterial and 
right internal jugular venous access, with a 10Fr catheter from the systemic 
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venous side and a 7Fr catheter from the systemic arterial side. A Swan-Ganz 
catheter was navigated to the pulmonary artery to re-evaluate the degree of 
intracardiac shunting and was subsequently used to support a 300 cm 0.035" 
Storq wire (Cordis, Fremont, CA, USA) to cross the VSD from the RV. Retrograde 
access from the LV was obtained with a Judkins Right 7 Fr catheter (Cordis, 
Freemont CA, USA), and subsequently, the wire was exchanged for an 
endovascular snare (EN Snare Endovascular Snare System, Merit Medical, South 
Jordan, UT, USA). The Storq wire was then captured from the arterial access and 
served as a rail to deliver the Amplatzer® TorqVue 10Fr Sheath system (St. Jude 
Medical, St. Paul, MN, USA) in a “bodyfloss” fashion. 
The Amplatzer® delivery sheath was railed across the tricuspid annulus and over 
the VSD in the LV. The Storq wire was externalized, the VSD occluder was loaded 
into the delivery system, and then it was deployed from the arterial to the venous 
side. Once properly positioned, intracavitary echocardiography was performed to 
confirm the occluder was stable, and there was no significant residual VSD.15 
Subsequently, the device was released, and the delivery sheath was withdrawn 
(Figure 2). 
 
Figure 2. Intracavitary echocardiogram and fluoroscopic appearance of ventricular 
septal defect (VSD) device across ventricular septum after deployment. Left panel: 
Fluoroscopic image of the TorqVue delivery system and VSD occluder 
successfully deployed (arrow). Note transseptal cannula for TandemHeart® 
support in place (*). Right panel: Intracavitary echocardiogram of VSD occluder 
device (arrow) in place and released. 
 
 
Patients with VSDs thought a priori not to be amenable to catheter-based device 
closure, or those who underwent a failed attempt at catheter-based device closure, 
underwent surgical repair as outlined in Gregoric et al.16 In this subset of patients, 
a median sternotomy was completed, and repairs were performed using 
cardiopulmonary bypass (CPB) to provide total cardiac and pulmonary support 
with a bloodless operative field, via ascending thoracic aortic and bicaval 
 
The VAD Journal:  Post-MI VAD Treatment with TandemHeart LV MSC Page 6 of 14 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
cannulation. The TH cannulae were maintained in place for postoperative LV 
MCS. Ascending thoracic aortic cross-clamping with the administration of 
cardioplegia (antegrade +/- retrograde) was used to render the operative field still. 
Trans-infarct left ventriculotomy was performed. The VSD was repaired using a 
woven Dacron patch sutured to a rim of healthy LV myocardium circumferentially 
using polypropylene suture. Depending upon intraoperative findings, either a 
standard or infarct exclusion patch repair was performed. After aortic cross-clamp 
release and initiation of inotropic and vasoactive support for the right-sided 
circulation, CPB was weaned and transitioned to TH pVAD support.  
If the patient remained in cardiogenic shock despite TH assistance or after initial 
echocardiographic evaluation, defects were considered not amenable to 
percutaneous nor surgical closure, or in case of failed surgical closure due size or 
refractory biventricular failure TH was surgically explanted and a SynCardia 
temporary Total Artificial Heart (TAH) (SynCardia Inc., Tucson, AZ, USA) was 
implanted as a bridge to transplant, as previously described.17 
After a successful percutaneous or surgical VSD closure, the TH was left in place 
for an additional 5-7 days to facilitate myocardial recovery and ensure end-organ 
perfusion and then surgically explanted, as previously described.11 
Outcome parameters included: (1) technical success, which was defined as 
successful closure of the VSD without evidence of significant residual VSD or 
device embolization, and (2) survival at (a) 30 days, and (b) 180 days. 
Eight patients included in the current manuscript were previously reported in 
Gregoric et al.,11 as they were contemporaneous with our TH bridging and 
catheter-based device closure investigation.   
Statistical Analysis 
All statistical analyses were performed using Stata Version 12 statistical software 
(College Station, TX, USA). Categorical (frequency) variables were expressed as 
percentages or ratios. Continuous variables were expressed as means and 
standard deviation (SD) or medians with interquartile ranges (IQR). A comparison 
of Qp/Qs ratios between different types of MCS was performed with the two-
sample Wilcoxon rank-sum (Mann-Whitney) test. 
 
Results 
Over the course of 5 years and 7 months, 23 patients were admitted for 
management of post-MI VSD.  All patients in this group suffered VSD as a result of 
poor initial reperfusion or late presentation in the context of acute MI.  
Patient baseline characteristics are reported in Table 1; briefly, this cohort includes 
15 males and 8 females with a median age of 66 years (IQR 56 - 86). All patients 
had evidence of acute coronary syndrome a few days prior to the initial 
hospitalization. The date of MI and time to presentation could be identified in all 
patients except four due to the absence of typical signs and symptoms of angina.  
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Table 1. Baseline characteristics of patients in the entire group. 
 N=23 
Age, y 64 ± 14 
Men (%) 15 (65) 
Women (%) 8 (35) 
EKG infarct location  
   Anterior (%) 9 (39) 
   Inferior (%) 12 (52) 
    N/A (%) 2 (9) 
VSD site ICE assessment   
   Apical (%) 10 (42) 
   Basal (%) 13 (57) 
Cardiogenic shock (%) 20 (88) 
Median (IQR) pVAD time (days) 14 (10 – 25) 
Pre-procedure pVAD time (days) 8 (5 – 10) 
Post-procedure pVAD time (days) 6 (4-25) 
Median (IQR) initial Qp:Qs   2.40 (1.63-3.80) 
Abbreviations: VSD - ventricular septal defect, IQR - interquartile range, pVAD - 
percutaneous ventricular assist device, Qp - pulmonary blood flow, Qs - systemic blood 
flow. 
 
Twelve patients (52%) developed an inferior infarction. Two patients (9%) had 
non-obstructive coronary disease as confirmed by a coronary angiogram.  
Five patients (22%) were hemodynamically stabilized with pharmacological 
optimization (LV afterload reduction and inotropic support) alone, while 18 patients 
(78%) required mechanical hemodynamic support based on the primary 
assessment (Figure 3). Of those requiring MCS, 12 patients received IABP 
support, and 6 received TH support. Seven of 12 patients initially supported with 
IABP required a change to TH support, leaving only 5 patients on IABP.  
Once hemodynamically stable, the less compromised patients (n=10; 5 on medical 
therapy and 5 on IABP support) underwent percutaneous VSD repair, and all 
survived 30 days, and 9 of 10 were alive at 180 days post-procedure.  
In total, 13 patients received TH because they could not be hemodynamically 
stabilized either on medical therapy (n=6) or after IABP support (n=7). Of these, 8 
underwent percutaneous repair initially, while 5 had a direct surgical repair. Of the 
8 who underwent initial percutaneous repair, 3 failed and crossed over to surgical 
repair. Of the 5 TH patients who underwent percutaneous repair, 1 patient 
survived 30 days and was also alive at 180 days. 
All 3 TH patients who underwent failed percutaneous repair and converted to 
surgical repair survived 180 days. Of the 5 TH patients who underwent initial 
surgical repair, all survived 30 days, and 3 were alive at 180 days post-procedure. 
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Based on our prior experience with surgical repair,11 all patients on TH support  
prior to closure were continued on support after VSD closure. The median number 
of days on percutaneous ventricular assist device (pVAD) support was 14.0, with a 
median pre-procedural pVAD and post-procedural pVAD time of 6 days and 8 
days, respectively. 
The time-lapse between MI and defect closure ranged from 2 to 180 days, and 
only 4 patients underwent closure within 6 days. As a reflection of our delayed 
closure strategy (depicted in Figure 1), 18 patients with percutaneous closure had 
a procedural success rate of 78 % (14/18). A breakdown of these results includes 
3 patients who were switched to successful surgical repair; 1 patient implanted 
with a Total Artificial Heart, as previously described,17 due to severely depressed 
ventricular function secondary to the extended myocardial infarction; 4 patients 
with percutaneous closure died within 30 days. Five patients on TH underwent 
directly surgical VSD without attempting percutaneous closure due to the large 
size and location of VSD. 
The magnitude of left-to-right intracardiac shunt across the VSD correlated 
strongly with requirements for and types of MCS. The median Qp/Qs for this 
patient cohort was 2.37 (IQR 1.50-2.70). There is a significant difference in Qp/Qs 
ratio between the 10 patients who hemodynamically stabilized with medical 
therapy (n=5) or with IABP support only (n=5) and the 13 patients who required TH 
support to hemodynamically stabilize [median: 1.95 (IQR 1.50-2.40) vs. 2.70 (IQR 
2.10 - 3.50) respectively, P=0.046]. 
Most patients in this study underwent percutaneous closure with the Amplatzer® 
post-infarction VSD occluder device.15 Three patients required Amplatzer® 
muscular VSD closure device and one ASO device for percutaneous closure for 
their septal defects. 
There were no intraoperative or procedure-related deaths. The 30-day survival in 
all patients was 83%, with 180-day survival was 70%.  
 
 
Discussion 
Classical dogma regarding the pathogenesis of post-MI VSDs is that acute large 
trunk coronary arterial occlusion (generally the left anterior descending artery and 
right coronary artery, as they are responsible for interventricular septal blood 
supply) causes transmural septal infarction. This premise works in the setting of an 
isolated single coronary artery occlusive disease because robust coronary 
collateral circulation is commonly present in the setting of chronic multi-system 
coronary artery occlusive disease. After several days, large spatiotemporal 
gradients in the septal wall incur stress at the interfaces between infarcted and 
non-infarcted myocardium (due to the fact that the septum is exposed to high-
stress gradients as it is situated between the LV and RV). This stress results in 
ventricular septal rupture and VSD formation--a dynamic perforation of the 
ventricular septum at the interface between the necrotic and healthy myocardium. 
VSD is commonly seen in the apical septum in anterior infarctions and in the basal 
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region in inferior infarctions.18 Although relatively rare, VSD is associated with high 
morbidity and mortality if managed medically or with conventional surgery.  
Lundblad and colleagues describe a case series of post-MI VSD patients over a 
25-year study period, and report that concomitant surgical revascularization of all 
stenotic vessels, beyond the occluded one, decreased mortality at 30 days; this 
was attributed to the improved perfusion of the ischemic border zone and the 
consequently reduced risk of arrhythmias.19 
Another study reported improved survival for patients in whom VSD surgical repair 
was delayed by two weeks after infarction to allow stabilization of the defect size 
and sufficient maturation of the scar borders to hold sutures.20 Delayed post-MI 
VSD closure for proper defect sizing and effective anchoring was subsequently 
adopted by other groups,21,22 and it constituted one of the foundations of our 
procedural strategy to surgically manage post-MI VSD.11 Prior experience with 
patients undergoing surgical VSD repair11 and prior necropsy observations18 
support a 7-10 day post-MI delay period before the VSD is closed. VSDs are often 
observed to enlarge. This is thought to be due to the structural weakness of the 
infarcted septal tissue, and consequently, negatively impact the outcomes of 
catheter-based or open surgical closure due to dehiscence – thereby yielding 
residual VSD. However, the David infarct exclusion technique may be less prone 
to dehiscence.9 
The Amplatzer® post-infarction VSD occluder device, when properly sized, further 
circumvented some of the surgical challenges. The devise is a self-centering 
occluder that plugs the actual defect. The central part of the device fits the defect 
and is unaffected by the characteristics of the septal wall; its self-expanding 
properties allow for adjustments in the event of defect enlargement.  
Currently, percutaneous closure is becoming a widespread and widely accepted 
method to correct post-MI VSD, and this manuscript describes our experience with 
percutaneous closure strategy. Our outcomes (Figure 3) are similar to the results 
previously reported by Landzberg and Lock,23 Holzer et al.,24 and Egbe et al.21 In a 
recent series from the Mayo Clinic, investigators observed 83% survival at 30-days 
post-procedure and up to 5 years of follow up.21 
In a US registry, 30-day survival of 18 patients with percutaneous closure of post-
MI VSD was 72%; however, 10 (56%) of the patients developed shock prior to 
defect closure, and 8 (44%) of them needed to be hemodynamically stabilized with 
IABP. The majority of these patients underwent the procedure at least two weeks 
after diagnosis.22 
Although there are still limited clinical data to support delayed VSD closure (i.e., 
after the acute phase), the timing of the percutaneous closure is significantly 
influenced by the hemodynamic status of the patient. The presence of cardiogenic 
shock has been repeatedly associated with a dismal survival rate. Thiele et al25 
have reported their experience in percutaneous post-myocardial closure in 29 
patients performed within three days from presentation. Although the procedural 
success was 86%, the overall survival at 30 days was only 35% and was attributed 
to the large occurrence of left ventricular rupture, device late embolization, residual 
large shunt, and cardiogenic shock.  
 
The VAD Journal:  Post-MI VAD Treatment with TandemHeart LV MSC Page 11 of 14 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
Kapur et al26 used a male swine preclinical myocardial infarction model to show 
mechanically unloading the LV utilizing the TH reduced LV wall stress and 
activated signaling pathways that promoted myocardial salvage, even when 
coronary reperfusion was delayed. The TH provides direct left-sided cardiac 
unloading as opposed to venous arterial extracorporeal membrane oxygenation 
(VA-ECMO), which only indirectly volume-unloads the severely dysfunctional post-
MI LV; thus, it was the chosen device for the post-MI VSD cases. VA-ECMO with 
an IABP in place reduces LV afterload, but it was theorized that the LV volume-
unloading would be superior with TH pVAD support.  
Our strategy of combining delayed percutaneous closure and percutaneous 
hemodynamic support ensured both higher short- and long-term survival rates, 
even in the presence of a significant fraction of patients (86%) in some degree of 
cardiogenic shock that required TH support, similar to previously published reports 
of pVAD support prior to VSD repair.15,16,27,28 
Due to the retrospective nature of our analysis and the relatively small patient 
cohort, we cannot further define specific hemodynamic and/or clinical parameters 
whose presence may warrant TH implementation; however, our data do support a 
delay in VSD closure and the use of the Qp/Qs ratio. Patients who can be 
hemodynamically stabilized with medical therapy or IABP support will most likely 
still benefit from a post-acute intervention strategy (i.e., delay VSD closure for 
approximately two weeks to allow tissue granulation at the VSD). A high initial 
Qp/Qs ratio (i.e., greater than 2.4) might be a valuable predictive tool. We included 
the ratio along with other clinical variables in our algorithm as a trigger to 
mechanical support escalation and surgical VSD repair. However, future larger 
studies are warranted to confirm this algorithm. 
  
Conclusion 
In conclusion, post-MI VSD is associated with extremely high mortality in patients 
in cardiogenic shock. The introduction of mechanical support and delayed surgical 
intervention in hemodynamically unstable patients may improve outcomes. Larger 
and longer studies should be done to provide further evidence for guidelines to 
advance mechanical support in the early management of post-MI VSD. 
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